Selected article for: "human human and virus infection"

Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future
  • Document date: 2017_3_28
  • ID: 0fegsm1v_170
    Snippet: Ebola virus disease (EVD) is a severe, often fatal, zoonotic infection documented with most recent widespread outbreak in west Africa. It is caused by a virus of the Filoviridae family (genus Ebolavirus). The disease is transmitted from human to human via contact with body fluids of the patients, the incubation period is 1-21 days and case fatality rates range from 30 to 90% (Beeching et al., 2014) . A mAb named ZMapp is manufactured in the tobac.....
    Document: Ebola virus disease (EVD) is a severe, often fatal, zoonotic infection documented with most recent widespread outbreak in west Africa. It is caused by a virus of the Filoviridae family (genus Ebolavirus). The disease is transmitted from human to human via contact with body fluids of the patients, the incubation period is 1-21 days and case fatality rates range from 30 to 90% (Beeching et al., 2014) . A mAb named ZMapp is manufactured in the tobacco plant Nicotiana benthamiana to treat EVD patients and to improve public health. It contains a cocktail of different mAbs (MB-003, ZMab, c2G4, and c4G7) that work to avert the spread of the disease within the body (Qiu et al., 2014) . A recent study investigated the treatment of EVD patient with ZMapp, a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734. The patient is a first neonate documented to have successfully survived EVD (Dörnemann et al., 2017) .

    Search related documents:
    Co phrase search for related documents
    • body disease and Ebola virus: 1, 2
    • body disease and fatality rate: 1, 2
    • body disease and incubation period: 1, 2
    • body disease and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • body disease and recent study: 1, 2
    • body disease spread and public health: 1, 2
    • body fluid and Ebola virus: 1, 2
    • body fluid and Ebola virus disease: 1
    • body fluid and EVD Ebola virus disease: 1
    • body fluid and incubation period: 1
    • body fluid and patient body fluid: 1, 2, 3
    • body fluid and patient body fluid contact: 1, 2
    • body fluid and public health: 1, 2, 3
    • body fluid and widespread outbreak: 1
    • broad spectrum and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
    • broad spectrum and Ebola virus disease: 1, 2, 3, 4, 5, 6, 7, 8